Comparative Pharmacology
Head-to-head clinical analysis: BONTRIL PDM versus FASTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BONTRIL PDM versus FASTIN.
BONTRIL PDM vs FASTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phentermine is a sympathomimetic amine that acts as an appetite suppressant by stimulating the release of norepinephrine and dopamine in the hypothalamus, reducing food intake. Topiramate is a sulfamate-substituted monosaccharide that enhances GABAergic activity and inhibits glutamatergic neurotransmission via AMPA/kainate receptors, leading to appetite suppression and increased energy expenditure.
Sympathomimetic amine that promotes release of norepinephrine and dopamine from presynaptic nerve terminals in the hypothalamus, suppressing appetite.
Oral: 5-10 mg once daily in the morning; maximum 20 mg/day. Oral disintegrating tablet: 5-10 mg once daily.
30 mg orally once daily in the morning, administered as a single dose.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in adults, prolonged to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 16-20 hours for the immediate-release formulation. With sustained-release forms, effective half-life may extend to 24-34 hours due to prolonged absorption. Clinical context: time to reach steady state is about 3-5 days.
Renal: ~70% (unchanged), Fecal: ~30% (biliary excretion of metabolites).
Primarily renal (approximately 70-80% unchanged) and biliary/fecal (20-30% as metabolites). Urinary excretion is pH-dependent; acidic urine increases elimination.
Category C
Category C
Sympathomimetic Anorectic
Sympathomimetic Anorectic